BNP Paribas Arbitrage SA increased its holdings in shares of TESARO Inc (NASDAQ:TSRO) by 67.4% in the third quarter, according to its most recent filing with the SEC. The fund owned 5,567 shares of the biopharmaceutical company’s stock after acquiring an additional 2,241 shares during the period. BNP Paribas Arbitrage SA’s holdings in TESARO were worth $719,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. Exane Derivatives bought a new stake in shares of TESARO during the 3rd quarter worth approximately $106,000. Botty Investors LLC bought a new stake in shares of TESARO during the 2nd quarter worth approximately $140,000. Nordea Investment Management AB bought a new stake in shares of TESARO during the 2nd quarter worth approximately $167,000. Oppenheimer Asset Management Inc. raised its position in TESARO by 3,042.6% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock valued at $206,000 after purchasing an additional 1,430 shares in the last quarter. Finally, BB&T Securities LLC bought a new stake in TESARO during the 2nd quarter valued at $222,000.
TESARO Inc (TSRO) opened at $86.44 on Tuesday. TESARO Inc has a one year low of $79.03 and a one year high of $192.94. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.73 and a quick ratio of 4.35.
A number of brokerages have weighed in on TSRO. Robert W. Baird reaffirmed a “neutral” rating and set a $140.00 target price (down from $155.00) on shares of TESARO in a research report on Thursday, August 10th. Morgan Stanley reaffirmed an “overweight” rating and set a $183.00 target price on shares of TESARO in a research report on Thursday, August 10th. Jefferies Group set a $124.00 target price on TESARO and gave the company a “hold” rating in a research report on Thursday, August 17th. Credit Suisse Group set a $190.00 target price on TESARO and gave the company a “buy” rating in a research report on Friday, August 18th. Finally, BidaskClub raised TESARO from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 23rd. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. TESARO has an average rating of “Buy” and an average target price of $159.39.
In related news, Director James O. Armitage sold 10,000 shares of the business’s stock in a transaction on Monday, September 18th. The stock was sold at an average price of $117.13, for a total transaction of $1,171,300.00. Following the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $1,171,300. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Martin H. Jr. Huber sold 592 shares of the business’s stock in a transaction on Friday, September 22nd. The stock was sold at an average price of $118.60, for a total value of $70,211.20. Following the transaction, the senior vice president now owns 6,943 shares in the company, valued at $823,439.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 21,454 shares of company stock worth $2,707,012. 34.60% of the stock is owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “TESARO Inc (TSRO) Shares Bought by BNP Paribas Arbitrage SA” was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.chaffeybreeze.com/2017/12/05/tesaro-inc-tsro-shares-bought-by-bnp-paribas-arbitrage-sa.html.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related companies with MarketBeat.com's FREE daily email newsletter.